An Open-Label, Phase 1 Safety and Phase 2 Randomized Study of JCAR017 in Subjects with Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma (017004)
Clinical Trial Grant
Awarded By
Celgene Corporation
Start Date
July 24, 2019
End Date
June 30, 2026
Awarded By
Celgene Corporation
Start Date
July 24, 2019
End Date
June 30, 2026